Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canadian Study Suggests Drug-Eluting Stents May Improve Long-Term Survival

This article was originally published in The Gray Sheet

Executive Summary

Drug-eluting stents may provide a long-term mortality benefit over bare-metal stents for at least some patients, according to a Canadian registry study in the Oct. 4 New England Journal of Medicine

You may also be interested in...

Drug-Eluting-Stent Market Penetration At Nadir? Rebound Forecast At TCT

U.S. drug-eluting-stent market penetration reached an all-time low in September, but clinicians meeting last week in Washington, D.C., are confident new data will help to reverse the trend that began just over a year ago

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts